20 completed, 5 terminated, 3 unknown, 1 active not recruiting. 30 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 30 | Completed 20, Terminated 5, Unknown 3, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow Neoplasm Malignant: new trials by email Literature Review of Neoplasm Malignant trials Research Report on Neoplasm Malignant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors STRO-002 - Neoplasm Malignant | Phase 1 / Phase 2 | Completed | Tasly Pharmaceutical Group Co., Ltd | 19 | 2023-11-08 | 2026-04-06 |
| NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | NuCana plc | 19 | 2023-03-08 | 2026-07-23 |
| Phase 1 First-in-human Study of JS014 JS014, Interleukin 21 and humanized anti-human serum albumin VHH antibody, Pembrolizumab - anti-PD-1 antibody - Neoplasm Malignant, Neoplasm, Experimental | Phase 1 | Unknown | Anwita Biosciences | 60 | 2022-02-28 | 2023-09-06 |
| Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors SAR443216 IV, SAR443216 SC - Neoplasm Malignant, Breast Cancer | Phase 1 | Terminated | Sanofi | 44 | 2021-08-16 | 2025-09-15 |
| Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) XL102, Fulvestrant, Abiraterone - Neoplasm Malignant, Epithelial Ovarian Cancer | Phase 1 | Terminated | Exelixis | 52 | 2021-02-10 | 2024-05-14 |
| First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL SAR442257 - Neoplasm Malignant | Phase 1 | Terminated | Sanofi | 47 | 2020-07-24 | 2026-09-29 |
| A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma IK-175, IK-175 and nivolumab - Urothelial Carcinoma, Urothelial Carcinoma Bladder | Phase 1 | Completed | Ikena Oncology | 78 | 2019-12-18 | 2024-03-15 |
| HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors G207 - Neoplasms, Brain, Glioblastoma Multiforme | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 24 | 2019-09-12 | 2026-09-04 |
| A Study of PSB205 in Subjects With Advanced Solid Tumors PSB205 - Neoplasm Malignant | Phase 1 | Unknown | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | 64 | 2019-07-05 | 2020-11-25 |
| A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors XL092, Atezolizumab, Avelumab - Neoplasm Malignant, Renal Cell Carcinoma | Phase 1 | Active not recruiting | Exelixis | 325 | 2019-03-20 | 2024-11-19 |
| Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors SHR9146+SHR-1210, SHR9146+SHR-1210+Apatinib - Tumor, Solid, Cancer, Metastatic | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 23 | 2018-11-20 | 2022-11-04 |
| COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. COM701, COM701 with Opdivo (Nivolumab). - Advanced Cancer, Ovarian Cancer | Phase 1 | Completed | Compugen Ltd | 121 | 2018-09-06 | 2025-01-17 |
| Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors SAR408701, dexamethasone, naphazoline - Neoplasm Malignant | Phase 1 | Completed | Sanofi | 34 | 2017-10-17 | 2025-08-05 |
| A Study of SAR428926 in Patients With Advanced Solid Tumors SAR428926 - Neoplasm Malignant | Phase 1 | Completed | Sanofi | 34 | 2015-10-05 | 2018-08-22 |
| Evaluation of SAR408701 in Patients With Advanced Solid Tumors SAR408701 - Neoplasm Malignant | Phase 1 | Terminated | Sanofi | 254 | 2014-07-23 | 2025-02-10 |
| A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients SAR405838, Pimasertib - Neoplasm Malignant | Phase 1 | Completed | Sanofi | 26 | 2013-11-01 | 2016-02-25 |
| A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma SAR245408 - Neoplasm Malignant | Phase 1 | Completed | Sanofi | 18 | 2013-10-01 | 2016-04-22 |
| A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies Aflibercept AVE0005, Leucovorin, Irinotecan - Neoplasm Malignant | Phase 1 | Completed | Sanofi | 20 | 2013-09-01 | 2015-01-07 |
| Effect of SAR302503 on ECG Activity in Patients With Solid Tumors SAR302503 (TG101348), Placebo SAR302503, Panolosetron - Neoplasm Malignant | Phase 1 | Completed | Bristol-Myers Squibb | 60 | 2013-05-01 | 2025-03-05 |
| Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients SAR125844 - Neoplasm Malignant | Phase 1 | Completed | Sanofi | 70 | 2012-09-01 | 2016-02-17 |
Showing 20 of 30. Sign in to see all of them.
Neoplasms (30) · Neoplasm Metastasis (4) · Triple Negative Breast Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Renal Cell (2) · Carcinoma, Transitional Cell (2) · Endometrial Neoplasms (2) · Lung Neoplasms (2) · Stomach Neoplasms (2) · Astrocytoma (1) · Brain Diseases (1) · Brain Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Central Nervous System Diseases (1)
Neoplasms by Site (6) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Neoplasms by Histologic Type (5) · Urogenital Diseases (5) · Urogenital Neoplasms (5) · Breast Diseases (4) · Carcinoma (4) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Gastrointestinal Diseases (4) · Gastrointestinal Neoplasms (4) · Neoplasms, Glandular and Epithelial (4) · Neoplastic Processes (4) · Pathologic Processes (4)
XL147 (3) · Docetaxel (2) · Leucovorin (2) · Nivolumab (2) · SAR405838 (2) · XL765 (2) · aflibercept (2) · pembrolizumab (2) · tusamitamab ravtansine (2) · 2-(2-(2-methyl-2,3-dihydroindol-1-yl)-2-oxoethyl)-6-morpholin-4-yl-3H-pyrimidin-4-one (1) · Carboplatin (1) · Dexamethasone (1) · Diphenhydramine (1) · Fluorouracil (1) · Fulvestrant (1)
Sanofi (19) · Exelixis (2) · Anwita Biosciences (1) · Bristol-Myers Squibb (1) · Compugen Ltd (1) · Ikena Oncology (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · M.D. Anderson Cancer Center (1) · NuCana plc (1) · Qilu Puget Sound Biotherapeutics (dba Sound Biologics) (1) · Tasly Pharmaceutical Group Co., Ltd (1)
United States (17) · France (8) · Spain (8) · Belgium (6) · China (4) · Netherlands (4) · South Korea (4) · Japan (3) · United Kingdom (3) · Canada (2) · Czechia (2) · Italy (2) · Taiwan (2) · Australia (1) · Denmark (1)
Gregory Friedman, MD (1) · Karim Malek, MD (1) · TJ Chiou, MD (1) · Ying Cheng, Prof. (1)
PMID 25531046, PMID 28324749, PMID 28976556, PMID 30585255, PMID 32673446, PMID 35026412, PMID 37507802, PMID 37645622, PMID 40413667, PMID 41337813, PMID 42705861
2014 (1), 2015 (1), 2019 (1), 2023 (1)